Vident Advisory LLC Decreases Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Vident Advisory LLC lessened its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 28.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,029 shares of the company's stock after selling 820 shares during the period. Vident Advisory LLC's holdings in IDEXX Laboratories were worth $839,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Hantz Financial Services Inc. increased its stake in IDEXX Laboratories by 11.5% in the 4th quarter. Hantz Financial Services Inc. now owns 7,738 shares of the company's stock worth $3,199,000 after buying an additional 800 shares during the period. Paragon Capital Management Inc. increased its stake in IDEXX Laboratories by 25.7% in the 4th quarter. Paragon Capital Management Inc. now owns 3,820 shares of the company's stock worth $1,579,000 after buying an additional 782 shares during the period. Fiera Capital Corp increased its stake in IDEXX Laboratories by 12.3% in the 4th quarter. Fiera Capital Corp now owns 141,198 shares of the company's stock worth $58,377,000 after buying an additional 15,463 shares during the period. Lecap Asset Management Ltd. increased its stake in IDEXX Laboratories by 587.7% in the 4th quarter. Lecap Asset Management Ltd. now owns 5,701 shares of the company's stock worth $2,357,000 after buying an additional 4,872 shares during the period. Finally, Blue Zone Wealth Advisors LLC purchased a new position in IDEXX Laboratories in the 4th quarter worth about $3,958,000. Hedge funds and other institutional investors own 87.84% of the company's stock.

Insider Activity

In other news, Director M Anne Szostak sold 1,260 shares of the firm's stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total value of $645,548.40. Following the sale, the director now directly owns 1,801 shares in the company, valued at approximately $922,724.34. This trade represents a 41.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.98% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Barclays raised their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 4th. Morgan Stanley increased their target price on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a report on Monday, May 5th. Wall Street Zen upgraded shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Bank of America increased their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Finally, Piper Sandler increased their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a report on Monday, February 10th. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $536.00.

IDEXX Laboratories Stock Down 0.5%

Shares of NASDAQ:IDXX traded down $2.51 during trading on Friday, reaching $513.04. The stock had a trading volume of 106,726 shares, compared to its average volume of 648,769. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $530.60. The company has a market capitalization of $41.26 billion, a P/E ratio of 48.11, a PEG ratio of 3.41 and a beta of 1.52. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The firm's 50-day simple moving average is $447.90 and its 200 day simple moving average is $436.67.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, beating analysts' consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The business had revenue of $998.43 million for the quarter, compared to analysts' expectations of $998.25 million. During the same period last year, the business earned $2.71 EPS. The company's revenue was up 3.6% compared to the same quarter last year. As a group, research analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.